CRDF Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cardiff Oncology Inc (CRDF) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has promising developments in its pipeline and an attractive entry point according to analysts, the lack of immediate catalysts, weak technical indicators, and poor financial performance suggest holding off for now.
The stock's technical indicators are mixed. The MACD is positive and expanding, suggesting some bullish momentum, but the RSI is neutral and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The price is trading near resistance levels, with no clear breakout signal.
Analysts have reiterated a Buy rating with a reduced price target of $6-$10, citing the potential of the CRDF-004 trial results and an attractive entry point after recent selloffs.
No recent news or significant trading activity from insiders, hedge funds, or Congress. Financial performance shows declining net income and EPS, and the approval timeline for key drugs has been pushed to 2030.
In Q4 2025, revenue increased by 60.93% YoY to $243,000, but net income dropped by 38.75% YoY to -$7.22M, and EPS fell by 50% YoY to -0.11. The gross margin remained at 100%, but overall financials indicate weak profitability.
Piper Sandler and H.C. Wainwright maintain positive ratings, with price targets of $6 and $10 respectively. However, Piper Sandler has pushed the approval timeline for onvansertib to 2030, which may delay significant returns.
